Edition:
Deutschland

Elekta AB (publ) (EKTAb.ST)

EKTAb.ST on Stockholm Stock Exchange

73.05SEK
20 Nov 2017
Change (% chg)

0.00kr (+0.00%)
Prev Close
73.05kr
Open
--
Day's High
--
Day's Low
--
Volume
11,600
Avg. Vol
1,386,222
52-wk High
95.90kr
52-wk Low
66.90kr

EKTAb.ST

Chart for EKTAb.ST

About

Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer... (more)

Buy/Sell

Sell Hold Buy
3.12 Mean rating from 17 analysts

Overall

Beta: 0.91
Market Cap(Mil.): kr30,942.93
Shares Outstanding(Mil.): 368.59
Dividend: 0.50
Yield (%): 1.19
Photo

European shares suffer worst week since August as earnings growth slows

MILAN/LONDON European shares suffered their worst week in three months on Friday, as a slowdown in earnings growth and jitters in bond markets spurred profit-taking in a market that remains close to two-year highs.

Photo

European shares suffer worst week since August as earnings growth slows

MILAN/LONDON European shares suffered their worst week in three months on Friday, as a slowdown in earnings growth and jitters in bond markets spurred profit-taking in a market that remains close to two-year highs.

UPDATE 2-European shares suffer worst week since August as earnings growth slows

* Euro zone earnings beats 51 pct vs 72 pct on S&P500 (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)

BRIEF-Elekta says CE mark for Unity is expected during first half of 2018

* Elekta has decided to add additional functional imaging capabilities to its MR-linac (Unity) and to spend more time on validating its linac control system

BRIEF-Mclaren Health Care and Elekta mutually terminate long-term agreement

* Mclaren Health Care and Elekta have mutually agreed to terminate their long-term agreement.

BRIEF-Elekta and IBA partner to advance proton therapy treatments

* Eleketa and Ion Beam Applications (IBA) enter an mou regarding a comprehensive partnership including joint software development and sales to advance proton therapy treatments Source text for Eikon: Further company coverage: (Stockholm Newsroom)

BRIEF-Elekta and Brainlab collaborate to streamline treatment workflows for stereotactic radiation therapy

* Elekta and Brainlab collaborate to streamline treatment workflows for stereotactic radiation therapy Source text for Eikon: Further company coverage:

UPDATE 1-Elekta repeats margin target as Q1 core profit lags expectations

Aug 23 Radiotherapy gear maker Elekta posted on Wednesday lower quarterly core earnings than expected, but orders matched forecasts and the firm repeated a full-year margin target.

BRIEF-Elekta Q1 core profit lags expectations, orders in line

* Reuters poll average forecasts were for adjusted EBITA of 244 mln SEK, sales 2,148 mln, orders 2,736 mln

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.24%
Rohstoffe +0.24%
Industrie +0.15%
Konjunktur abhängige Waren & Dienstleistungen +0.07%
Konjunktur unabhängige Waren & Dienstleistungen +0.07%
Finanzindustrie -0.02%
Pharma +0.05%
Technologie +0.26%
Telekommunikation +0.08%

Nachrichten aus der Wirtschaft

Photo

EZB-Chef mahnt zum Abbau fauler Kredite in den Bankbilanzen

Frankfurt Für die Einführung einer gemeinsamen Einlagensicherung in Europa ist laut EZB-Chef Mario Draghi der Abbau fauler Kredite in den Bankbilanzen entscheidend.